WI Harper–backed Neuracle Technology Co., Ltd. has officially completed a new financing round, raising RMB 60 million. To date, Neuracle has completed three rounds of funding, bringing its total to over RMB 100 million. This round was led by China Control Fund, China Development Fund, China Development Frontier Fund, and BV Baidu Ventures.

Neuracle develops, manufactures, and provides technical services for brain-computer interface (BCI) systems based on its proprietary technology. The company offers end-to-end solutions for neuroscience research and clinical applications in neurological diagnosis, treatment, and rehabilitation. Its client base includes top institutions in brain science and clinical medicine. According to General Manager Huang Xiaoshan, the new funding will accelerate R&D of clinical products and advance the development of minimally invasive implant feedback therapy and BCI-based intelligent rehabilitation.

As the first global cross-border VC firm to establish a presence in the Asia-Pacific region, WI Harper Group continues to invest in cutting-edge sectors such as AI, smart manufacturing, big data, AR/VR, 5G, fintech, climate tech, and especially brain-machine interface technologies. These technologies are driving transformation in healthcare and beyond. Wang Shuai, VP at WI Harper Group, remarked:

“The rapid evolution of BCI and its expansion into new verticals reflects both its technological maturity and the emerging era of human-machine integration.”

From Sci-Fi to Reality: BCI Technology Comes of Age

Today, what once belonged to science fiction—controlling machines with thoughts—is becoming reality. BCI technology enables this by translating brain signals into actionable commands for external devices. Recent innovations also enable two-way interaction, allowing input back into the brain, forming a hybrid brain+machine intelligence system.

BCI applications now span clinical medicine, education, gaming, and consumer electronics. The technology is drawing the attention of tech giants and investors alike. Neuralink, founded by Elon Musk and backed by over $100 million in funding, recently released a BCI system supporting closed-loop neuromodulation for diagnosing and treating neurological disorders such as epilepsy, depression, Parkinson’s, and Alzheimer’s. Meta (Facebook) is also reportedly investing in BCI to help individuals with speech impairments.

BCI is not a new field—it’s supported by over a decade of research. In 2013, the U.S. launched its BRAIN Initiative, aimed at mapping brain function and developing treatments for brain disorders. Its budget grew to $434 million by 2017. That same year, the EU launched the 10-year Human Brain Project, involving 135 institutions across 26 countries.

China’s “Brain Plan” and Neuracle’s Role

China has also prioritized BCI through its “13th Five-Year Plan” and “Brain Science and Brain-like Research” initiative, a major project under the Science & Technology Innovation 2030 strategy. National and provincial centers in Beijing, Shanghai, Tianjin, Zhejiang, and Shandong are forming a collaborative framework focused on understanding neural mechanisms (the “body”) and developing diagnostic/treatment technologies and brain-inspired intelligence (the “two wings”).

Technically, BCI can be invasive (implanted) or non-invasive (external). While invasive BCI provides more accurate neuron-level data, it carries medical risks. Non-invasive BCI, while safer, captures only surface EEG data. Neuracle focuses on minimally invasive BCI that combines safety with deeper data access, addressing the limitations of both approaches.

A Leading BCI Platform with Market Impact

Li Chaowen, VP of Investment at China Industrial Investment Fund, said:

“BCI is a complex, frontier technology with wide applications—from clinical treatment to consumer tech. Neuracle’s team, originating from Tsinghua University’s world-class neuroengineering lab, has over a decade of deep domain expertise. We see tremendous potential in their work.”

Neuracle’s platform powers products across multiple fields, especially in brain research and neurological diagnostics. In 2018, it held over 30% market share in China’s BCI research market. Clients include top academic institutions like Tsinghua University, Chinese Academy of Sciences, Shanghai Jiao Tong University, and UCSD. Its products offer advanced EEG signal acquisition and analysis with strong anti-interference capabilities, meeting or surpassing international standards.

At the recent BCI Brain-Controlled Robot Competition and the 3rd China Brain-Machine Interface Competition in Beijing, Neuracle supplied the signal acquisition and data analysis platforms. In one event, Wei Siwen achieved a national record of 691.55 bits per minute, equivalent to typing 69 Chinese characters per minute using only BCI.

From Diagnostics to Therapy

Neuracle’s products include:

• EEG and Evoked Potential Systems for neurological diagnostics (e.g., epilepsy, cerebral hemorrhage)
• High-frequency, high-lead EEG systems used in neurosurgical planning
  These systems are core components of China’s “12th Five-Year Plan” for medical device innovation and are now in widespread deployment.

For treatment, Neuracle is advancing:

• Minimally invasive implant feedback therapy (e.g., for Alzheimer’s and epilepsy)
• BCI-powered intelligent active rehabilitation (e.g., for stroke recovery)

In the latter, the system detects signals from surviving neurons, interprets them, and controls robotic devices to perform intended movements. Feedback loops help the brain “relearn” motor skills, leveraging neuroplasticity for recovery.